What do you do if your GLP-1 refill is delayed?

Key takeaways

Dr. Linda's take

The message I get on a Tuesday night is almost never "how soon can I refill." It is "my pen was supposed to be here Friday, the pharmacy says it is on backorder, and I do not know what happens to me now." That question is different from a timing question. Timing questions have answers you can look up. Delay questions feel like the floor moved, because someone else is holding the calendar and you are the one who has to live in the gap.

Here is the reframe I offer. A delayed refill is an access failure, and access failures have owners, phone trees, and appeal paths. They are frustrating and they are solvable. Your job in that week is not to white-knuckle your way through it or to improvise. It is to find out which link in the chain actually broke, tell your prescriber that the gap exists, and let the clinical decision about what comes next be made by someone with your chart in front of them. This article picks up where the timing guides end: the refill was due, and it simply did not come.

Why does a late refill feel scarier than it actually is pharmacologically?

These are weekly medicines for a reason, and that reason is how slowly they clear. Semaglutide has a half-life (t1/2) of approximately 7 days, which supports its once-weekly administration. Tirzepatide has an elimination half-life of approximately 5 days, enabling once-weekly dosing. That is a very different profile from a daily pill, where missing a day can mean the drug is essentially gone by the next morning.

The practical consequence is that a shipment slipping by a few days is not the same event as stopping. The Wegovy label notes that with an elimination half-life of approximately 1 week, semaglutide will be present in the circulation for about 5 to 7 weeks after the last injectable dose. Steady-state plasma tirzepatide concentrations were achieved following 4 weeks of once weekly administration, which is also why the level you have built up does not disappear the moment a delivery is late. None of that means a gap is nothing. It means the fear that one late week undoes everything is out of proportion to the pharmacology, and you can make calls from a calmer place than the one the pharmacy voicemail put you in.

What do the labels actually say about a late dose?

The instructions differ by product, which is one reason generic internet advice about a "48 hour rule" causes so much confusion. Read the label for the specific product in hand rather than the one a friend takes.

For tirzepatide products, the Zepbound and Mounjaro labels instruct patients to administer the medication as soon as possible within 4 days (96 hours) after a missed dose, and to skip it and administer the next dose on the regularly scheduled day if more than 4 days have passed. Those labels also state that the day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours), which matters when a delayed delivery lands on the wrong weekday and shifts your whole rhythm, and our pillar guide on how soon a refill is actually due covers those baseline timing rules in full.

For semaglutide, the Wegovy label describes a shorter window: if one dose is missed and the next scheduled dose is more than 2 days away, administer the injection as soon as possible, and if the next scheduled dose is less than 2 days away, do not administer that dose and resume dosing on the regularly scheduled day of the week. Our companion piece on a single missed dose covers that one-week scenario in more depth.

What does the label say about restarting after a longer gap?

This is the part that surprises people, and it is the real reason a multi-week backorder is worth a conversation rather than a shrug. A long gap can change where treatment restarts, not just when.

If 2 or more consecutive doses of Wegovy injection are missed, the label directs that dosage escalation be reinitiated at a lower dosage to reduce the risk of gastrointestinal adverse reactions. In plain terms, the label anticipates that tolerance built up over weeks can fade over a long interruption, and it builds re-escalation into the instructions rather than assuming you pick up exactly where you left off. That is a clinical judgment call for your prescriber, informed by how long the gap actually ran. It is also a good argument for telling the office about a delay while it is happening instead of after it resolves, so the restart plan is made deliberately rather than in a rush.

Who do you call first when the refill does not arrive?

Work the chain in order. Most delays break at one specific link, and calling the wrong link first costs days.

Start with the pharmacy, because they can see the actual status: on order, on backorder, out of stock at this location but available at another, or waiting on something. Ask them to name the reason. If it is a stock issue at one location, ask whether the prescription can be transferred, and whether a different dispensing channel is available.

Next, the prescribing office. They need to know a gap is opening, both so the restart can be planned and so they can re-send or rewrite the prescription if the pharmacy never received it or if it needs to route elsewhere. Prescriptions get lost between systems more often than anyone likes to admit.

Then the insurer. If the block is coverage rather than supply, the pharmacy will usually say "rejected" rather than "backordered," and the fix is administrative. Our guide to coupons and prior authorization walks through what an approval packet needs, and our breakdown of what coverage actually costs helps you price the gap if you decide to bridge it out of pocket. If you are still deciding how you want to be covered at all, the eligibility quiz is a reasonable starting point.

How do you tell a supply problem from a coverage problem?

They feel identical from the couch and they are fixed in completely different ways, so it is worth pinning down which one you have.

Supply problems are national and verifiable. The FDA maintains a public drug shortage database, and it defines the terms precisely: a drug is currently in shortage if the demand or projected demand for the drug within the United States exceeds the supply of the drug, and a shortage is considered resolved when FDA determines that supply is no longer exceeded by demand or projected demand. That list is updated daily with new and resolved shortages, as well as additional information the agency receives from product suppliers on their manufacturing capacity. Because status changes over time, check it yourself on the day you need the answer rather than trusting an article, including this one, about what was true months ago.

Coverage problems are personal and local to your plan. A prior authorization that expired, a formulary change at the start of a plan year, a step therapy requirement, a switch in pharmacy benefit manager, or a quantity limit that no longer matches your prescription will all show up as a refill that simply will not fill. Those never appear on a federal shortage list, because nothing is actually scarce. The tell is usually in the language: "we cannot get it" points one direction, "it is not covered" or "it needs authorization" points the other.

The bottom line

A delayed refill is a logistics failure that your body is better buffered against than your nervous system believes, because weekly medicines clear slowly and the level you built does not vanish in a week. What the labels do take seriously is a longer interruption, which is why the instructions for restarting after multiple missed doses exist at all. So treat the delay as a task list rather than a verdict: get the real reason from the pharmacy, put the gap on your prescriber's radar while it is still open, check whether the block is supply or coverage, and let the person managing your care decide how treatment resumes. You are allowed to be annoyed at the system and still be fine.

References

1. Novo Nordisk Inc. (2026). WEGOVY (semaglutide) injection, for subcutaneous use; WEGOVY (semaglutide) tablets, for oral use - prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (Accessed 2026-07-20).
2. Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use - prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (Accessed 2026-07-20).
3. Eli Lilly and Company (2026). MOUNJARO (tirzepatide) injection, for subcutaneous use - prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0 (Accessed 2026-07-20).
4. Min JS, Jo SJ, Lee S, Kim DY, Kim DH, Lee CB, Bae SK (2025). A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist. Drug Design, Development and Therapy (via PMC). https://pmc.ncbi.nlm.nih.gov/articles/PMC12052016/ (Accessed 2026-07-20).
5. U.S. Food and Drug Administration (2026). Frequently Asked Questions about Drug Shortages. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-shortages/frequently-asked-questions-about-drug-shortages (Accessed 2026-07-20).

---

*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*

*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-21.*